C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H2 2018
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H2 2018
SUMMARY
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report C-X-C Chemokine Receptor Type 2 - Pipeline Review, H2 2018, outlays comprehensive information on the C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - CXCR2 or Interleukin 8 receptor, beta is a chemokine receptor. It binds to IL8 with high affinity, and transduces the signal through a G-protein-activated second messenger system. This receptor also binds to chemokine (C-X-C motif) ligand 1 and has shown a major role in serum-dependent melanoma cell growth.
This receptor mediates neutrophil migration to sites of inflammation. The angiogenic effects of IL8 in intestinal microvascular endothelial cells are found to be mediated by this receptor. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Respiratory, Cardiovascular, Central Nervous System, Dermatology, Infectious Disease and Metabolic Disorders which include indications Chronic Obstructive Pulmonary Disease (COPD), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Breast Cancer, Autoimmune Disorders, Bronchopulmonary Dysplasia, Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Inflammation, Inflammatory Pain, Liver Transplant Rejection, Lung Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Transplant Rejection, Post-Operative Pain, Pulmonary Inflammation, Solid Tumor, Type 1 Diabetes (Juvenile Diabetes) and Unspecified Influenza Virus Infections.
Furthermore, this report also reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report C-X-C Chemokine Receptor Type 2 - Pipeline Review, H2 2018, outlays comprehensive information on the C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - CXCR2 or Interleukin 8 receptor, beta is a chemokine receptor. It binds to IL8 with high affinity, and transduces the signal through a G-protein-activated second messenger system. This receptor also binds to chemokine (C-X-C motif) ligand 1 and has shown a major role in serum-dependent melanoma cell growth.
This receptor mediates neutrophil migration to sites of inflammation. The angiogenic effects of IL8 in intestinal microvascular endothelial cells are found to be mediated by this receptor. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Respiratory, Cardiovascular, Central Nervous System, Dermatology, Infectious Disease and Metabolic Disorders which include indications Chronic Obstructive Pulmonary Disease (COPD), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Breast Cancer, Autoimmune Disorders, Bronchopulmonary Dysplasia, Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Inflammation, Inflammatory Pain, Liver Transplant Rejection, Lung Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Transplant Rejection, Post-Operative Pain, Pulmonary Inflammation, Solid Tumor, Type 1 Diabetes (Juvenile Diabetes) and Unspecified Influenza Virus Infections.
Furthermore, this report also reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2)
- The report reviews C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Overview
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Companies Involved in Therapeutics Development
AstraZeneca Plc
ChemoCentryx Inc
Dompe Farmaceutici SpA
Eli Lilly and Co
GlaxoSmithKline Plc
Merck & Co Inc
Syntrix Biosystems Inc
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Drug Profiles
AZD-5069 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-5069 + durvalumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
danirixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DF-2755A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize CXCR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ladarixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3041658 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize CXCR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
navarixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-G31P - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reparixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CCR1 and CXCR2 for Solid and Hematological tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-517 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-576 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-682 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Dormant Products
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Discontinued Products
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Product Development Milestones
Featured News & Press Releases
Sep 04, 2017: GSK presents data on Danirixin at ERS
Apr 26, 2017: Trial investigates use of asthma drug for patients with heart conditions
Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells
Oct 05, 2015: Study Available at Fox Chase Cancer Center Evaluates the Use of Reparixin in Combination with Paclitaxel for the Treatment of Metastatic Triple Negative Breast Cancer
Oct 01, 2014: Dompe commitment in oncology against cancer stem cells
Sep 25, 2013: Pharmaceutical company Domp? launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation
Jul 10, 2013: Domp? announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true
Dec 06, 2012: Domp? Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium
Oct 23, 2012: Domp? Announces Enrollment Of First Patient In Phase III Trial On Reparixin
Oct 24, 2011: Domp? Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress
Oct 13, 2011: Domp?'s Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Overview
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Companies Involved in Therapeutics Development
AstraZeneca Plc
ChemoCentryx Inc
Dompe Farmaceutici SpA
Eli Lilly and Co
GlaxoSmithKline Plc
Merck & Co Inc
Syntrix Biosystems Inc
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Drug Profiles
AZD-5069 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-5069 + durvalumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
danirixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DF-2755A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize CXCR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ladarixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3041658 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize CXCR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
navarixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-G31P - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reparixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CCR1 and CXCR2 for Solid and Hematological tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-517 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-576 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-682 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Dormant Products
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Discontinued Products
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Product Development Milestones
Featured News & Press Releases
Sep 04, 2017: GSK presents data on Danirixin at ERS
Apr 26, 2017: Trial investigates use of asthma drug for patients with heart conditions
Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells
Oct 05, 2015: Study Available at Fox Chase Cancer Center Evaluates the Use of Reparixin in Combination with Paclitaxel for the Treatment of Metastatic Triple Negative Breast Cancer
Oct 01, 2014: Dompe commitment in oncology against cancer stem cells
Sep 25, 2013: Pharmaceutical company Domp? launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation
Jul 10, 2013: Domp? announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true
Dec 06, 2012: Domp? Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium
Oct 23, 2012: Domp? Announces Enrollment Of First Patient In Phase III Trial On Reparixin
Oct 24, 2011: Domp? Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress
Oct 13, 2011: Domp?'s Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by ChemoCentryx Inc, H2 2018
Pipeline by Dompe Farmaceutici SpA, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Syntrix Biosystems Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by ChemoCentryx Inc, H2 2018
Pipeline by Dompe Farmaceutici SpA, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Syntrix Biosystems Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AstraZeneca Plc
ChemoCentryx Inc
Dompe Farmaceutici SpA
Eli Lilly and Co
GlaxoSmithKline Plc
Merck & Co Inc
Syntrix Biosystems Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AstraZeneca Plc
ChemoCentryx Inc
Dompe Farmaceutici SpA
Eli Lilly and Co
GlaxoSmithKline Plc
Merck & Co Inc
Syntrix Biosystems Inc
